期刊文献+

膀胱过度活动症的抗胆碱治疗及其不良反应 被引量:2

Therapy and Adverse Reactions of the Application of Antimuscarinic Drugs for Overactive Bladder
原文传递
导出
摘要 膀胱过度活动症(overactive bladder,OAB)是一种令人烦恼的疾病,它影响着人们生活的质量。病人常常表现为尿急,伴有或不伴有急迫性尿失禁,通常有尿频和夜尿的症状。虽然膀胱过度活动症的病因不是很明确,但是抗胆碱药物作为其治疗的基石,在减少膀胱储尿期的收缩,增加膀胱的容量,起着重要的作用。这类药物具有一定的安全性,副作用小,并且有着相似的疗效。尽管如此,当治疗膀胱过度活动时,抗胆碱药物种类的选择,其治疗的预期利弊平衡也应在考虑之中,尤其是合并有中枢神经系统或者心脑血管系统疾病的老年患者。本文通过查阅国内外新近相关的文献,从受体的选择,临床应用和不良反应等方面对7种抗胆碱药物进行综述。 Oveactive bladder (OAB) is a bothersome condition that affects patients' quality of life. Patients present with urgency with or without urinary incontinence and often have urinary frequency and nocturia. The etiology is largely unknown, however, the antimuscarinic agents, as the cornerstone in the management of OAB, play an important role in decreasing the ability of the bladder to contract during the storage phase and so increase the bladder capacity. As a class, these agents are safe and have mild adverse effects and similar efficacy though, it is important to consider the risk/benefit balance of antimuscarinic agents when selecting OAB treatment, especially elderly patients with central nervous system or cardiovascular system disease. We herein review the receptor selectivity, clinical application and adverse event of the seven antimuscarinic agents through retrieving the related literatures in and out of China.
出处 《现代生物医学进展》 CAS 2014年第24期4790-4793,共4页 Progress in Modern Biomedicine
关键词 抗胆碱 膀胱过度活动 药物治疗 Antimuscarinic Overactive bladder Medical treatment
  • 相关文献

参考文献33

  • 1Sellers DJ, McKay N. Developments in the pharmacotherapy of the overactive bladder[J]. Curr Opin Urol, 2007, 17(4): 223-230.
  • 2Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder[J]. Urology, 2002, 60(5): 7-12.
  • 3Robinson D, Cardozo L. New drug treatments for urinary incontinence [J]. Maturitas, 2010, 65(4): 340-347.
  • 4Fortin MP, Rouch I, Dauphinot V, et al. Effects of anticholinergic drugs on verbal episodic memory function in the elderly: a retrospective, cross-sectional study[J]. Drugs Aging, 2011, 28(3): 195-204.
  • 5Novara G, Galfano A, Secco S, et al. A systematic review and meta-an- alysis of randomized controlled trials with antimuscarinic drugs for overactive bladder[J]. Eur Urol, 2008, 54(4): 740-763.
  • 6Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomised, double blind, placebo controlled, multicentre study [J]. J Urol, 2009, 181(4): 1764-1772.
  • 7Sand PK, Davila GW, Lucente VR, et al. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome[J]. Am J Obstet Gynecol, 2012, 206(2): 168. e1-6.
  • 8MacDiarmid SA. The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy [J]. Rev Obstet Gynecol, 2009, 2(2): 116-121.
  • 9Gotoh M, Yokoyama O, Nishizawa O. Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blin- d, placebo-controlled trial[J]. Int J Urol, 2011, 18(5): 365-373.
  • 10De Mey C, Mateva L, Krastev Z, et al. Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine [J]. J Clin Pharmacol, 2011, 51 (3): 397-405.

同被引文献17

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部